Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdvaMed on competitive bidding

This article was originally published in The Gray Sheet

Executive Summary

In Oct. 6 1comments, AdvaMed reiterates durable medical equipment suppliers' concerns about beneficiary access to quality products, initially raised at CMS' Sept. 27-28 Program Advisory & Oversight Committee meeting on the impending DME competitive bidding program (2"The Gray Sheet" Oct. 3, 2005, p. 15). AdvaMed also asks CMS to consider the role of small pharmacies as product suppliers, and to look at how small manufacturers that directly supply single products might be included in the program. The trade group will submit comments on the proposed quality standards discussed at the meeting as well (3"The Gray Sheet" Oct. 3, 2005, p. 16)...

You may also be interested in...



Panel Advises CMS To Relax Quality Standards For DMEPOS Suppliers

CMS draft quality standards for DMEPOS suppliers may be too prescriptive and could exclude small suppliers from participating in competitive bidding, Program Advisory & Oversight Committee members suggested Sept. 26

Diabetes Products Should Be Exempt From Competitive Bidding – Panel

Supplier and manufacturer stakeholders are urging CMS to exclude blood glucose testing products from the impending DMEPOS competitive bidding program

COVID Mutants: Vaccine Changes Likely To Need Immunogenicity Studies, Not Big Efficacy Trials

US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. But how to know what variants need a limited study and which one need a big one will be an ongoing challenge, NIH's Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel